Table 3.

Necroptosis inhibitors under clinical development.

Compound Name	Target	Phase	Disease Condition	Identifier	Study Type	Status (Oct 2019)
GSK2982772	RIPK1	II	Ulcerative colitis	NCT02903966	With placebo	Completed
		I	Rheumatoid arthritis	NCT02858492	With placebo	Completed
		II	Psoriasis	NCT02776033	With placebo	Completed
GSK3145095		I	Solid tumors	NCT03681951	With Pembrolizumab	Terminated
Dabrafenib	RIPK3	IV	Melanoma Non-small cell lung cancer Solid tumor Rare cancers High grade glioma	NCT03340506	With trametinib	Recruiting
		II	Metastatic colorectal cancer	NCT03668431	With trametinib and PDR001	Recruiting
		II	Melanoma	NCT01682213	Single agent	Completed
		II	BRAF Mutation-Positive Malignant Melanoma and Brain Metastases	NCT02974803	With trametinib and stereotactic radiation	Active, not recruiting
		II	Metastatic Melanoma (Carrying BRAF V600 Mutation)	NCT02052193	With vemurafenib	Terminated
		III	Malignant Melanoma	NCT03551626	With trametinib	Recruiting
Ponatinib	RIPK/RIPK3		Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)	NCT01592136	Expanded Access	Approved for marketing
		II	Non-small cell lung cancer	NCT01813734	Single agent	Completed
		II	Leukemia	NCT01570868	Single agent	Terminated
		II/III	Non-small cell lung cancer head and neck Cancer	NCT01761747	Single agent	Terminated
		I/II	Acute myeloid leukemia	NCT02428543	With cytarabine	Recruiting
		II	Medullary thyroid cancer	NCT03838692	Single agent	Not yet recruiting
Pazopanib	RIPK1	I	Renal cell carcinoma Soft tissue sarcoma Metastatic disease	NCT02795819	With AR-42	Terminated
		II	Renal Cell carcinoma	NCT01545817	Pazopanib followed by everolimus	Terminated
DNL747	RIPK1	I	AD	NCT03757325	With Placebo	Recruiting
		I	ALS	NCT03757351	With Placebo	Recruiting
17AAG	HSP90	II	Anaplastic Large Cell Lymphoma Recurrent Adult Hodgkin Lymphoma Recurrent Mantle Cell Lymphoma	NCT00117988	Single agent	Completed
		I	Unspecified Adult Solid Tumor, Protocol Specific	NCT00121264	With sorafenib tosylate	Completed
		I	Relapsed or Refractory Hematologic Cancer	NCT00103272	With bortezomib	Terminated
IPI-504	HSP90	I	Solid Tumors	NCT00606814	With Docetaxel	Completed
		I	Multiple Myeloma	NCT00113204	Single agent	Completed
		II	Prostate Cancer	NCT00564928	Single agent	Completed